A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study

Ophthalmology

Volumn 121, Issue 12, 2014, Pages 2473-2481

  Gillies, Mark C ^a   Lim, Lyndell L ^b   Campain, Anna ^a   Quin, Godfrey J ^a   Salem, Wedad ^a   Li, Ji ^a   Goodwin, Stephanie ^a   Aroney, Christine ^a   McAllister, Ian L ^c   Fraser Bell, Samantha ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; DELAYED RELEASE FORMULATION; DRUG IMPLANT; MONOCLONAL ANTIBODY;

ADULT; ANGINA PECTORIS; ARTICLE; CATARACT; CENTRAL MACULAR THICKNESS; CEREBROVASCULAR ACCIDENT; CHORIORETINITIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; IMPACT OF VISION IMPAIRMENT QUESTIONNAIRE; INTRAOCULAR PRESSURE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; THORAX PAIN; TREATMENT DURATION; VISUAL ACUITY; AGED; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIABETIC RETINOPATHY; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; RETINA MACULA LUTEA; THERAPEUTIC USE;

AGED; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGRESSION ANALYSIS; VISUAL ACUITY;

EID: 84922192847     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.07.002     Document Type: Article

References (32)

1. S.E. Moss, R. Klein, and B.E. Klein The 14-year incidence of visual loss in a diabetic population Ophthalmology 105 1998 998 1003
2. J.W. Yau, S.L. Rogers, R. Kawasaki Meta-Analysis for Eye Disease (META-EYE) Study Group Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 35 2012 556 564
3. P. Mitchell, T.W. Wong Diabetic Macular Edema Treatment Guideline Working Group Management paradigms for diabetic macular edema Am J Ophthalmol 157 2014 505 513
4. P. Mitchell, F. Bandello, U. Schmidt-Erfurth RESTORE Study Group The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
5. P. Massin, F. Bandello, and J.G. Garweg Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study Diabetes Care 33 2010 2399 2405
6. D.V. Do, Q.D. Nyuyen, A.A. Khwaja READ-2 Study Group Ranibizumab for Edema of the Macula in Diabetes Study: 3-year outcomes and the need for prolonged frequent treatment JAMA Ophthalmol 131 2013 139 145
7. Diabetic Retinopathy Clinical Research Network, M.J. Elman, H. Qin, and L.P. Aiello Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results Ophthalmology 119 2012 2312 2318
8. Q.D. Nguyen, D.M. Brown, D.M. Marcus RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
9. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
10. R. Rajendram, S. Fraser-Bell, and A. Kaines A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-months data: report 3 Arch Ophthalmol 130 2012 972 979
11. M.B. Sultan, D. Zhou, J. Loftus Macugen 1013 Study Group A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema Ophthalmology 118 2011 1107 1118
12. D.V. Do, Q.D. Nguyen, D. Boyer DA VINCI Study Group One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 119 2012 1658 1665
13. M.C. Gillies, F.K. Sutter, and J.M. Simpson Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial Ophthalmology 113 2006 1533 1538
14. M.C. Gillies, J.M. Simpson, and C. Gaston Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema Ophthalmology 116 2009 2182 2187
15. M.C. Gillies, I.L. McAllister, and M. Zhu Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial Ophthalmology 118 2011 866 872
16. J.E. Chang-Lin, M. Attar, and A.A. Acheampong Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant Invest Ophthalmol Vis Sci 52 2011 80 86
17. J.A. Haller, B.D. Kuppermann, M.S. Blumenkranz Dexamethasone DDS Phase II Study Group Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema Arch Ophthalmol 128 2010 289 296
18. D.S. Boyer, D. Faber, S. Gupta Ozurdex CHAMPLAIN Study Group Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients Retina 31 2011 915 923
19. P. van Wijngaarden, D.J. Coster, and K.A. Williams Inhibitors of ocular neovascularization: promises and potential problems JAMA 293 2005 1509 1513
20. E.L. Lamoureux, J.F. Pallant, and K. Pesudovs The Impact of Vision Impairment Questionnaire: an evaluation of its measurement properties using Rasch analysis Invest Ophthalmol Vis Sci 47 2006 4732 4741
21. E.L. Lamoureux, J.F. Pallant, and K. Pesudovs The effectiveness of low-vision rehabilitation on participation in daily living and quality of life Invest Ophthalmol Vis Sci 48 2007 1476 1482
22. K. Pesudovs, L.E. Caudle, G. Rees, and E.L. Lamoureux Validity of a visual impairment questionnaire in measuring cataract surgery outcomes J Cataract Refract Surg 34 2008 925 933
23. R.P. Finger, E. Fenwick, and M. Marella The impact of vision impairment on vision-specific quality of life in Germany Invest Ophthalmol Vis Sci 52 2011 3613 3619
24. S.L. Zeger, K.Y. Liang, and P.S. Albert Models for longitudinal data: a generalized estimating equation approach Biometrics 44 1988 1049 1060
25. S. Hollis, and F. Campbell What is meant by intention to treat analysis? Survey of published randomised controlled trials BMJ 319 1999 670 674
26. G.N. Masters A Rasch model for partial credit scoring Psychometrika 47 1982 149 174
27. J.H. Song, Y.T. Hong, and O.W. Kwon Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection Graefes Arch Clin Exp Ophthalmol 246 2008 1775 1778
28. P.A. Campochiaro, D.M. Brown, A. Pearson FAME Study Group Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema Ophthalmology 118 2011 626 635
29. K. Kriechbaum, S. Prager, G. Mylonas Diabetic Retinopathy Research Group Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results Eye (Lond) 28 2014 9 15
30. D.G. Callanan, S. Gupta, D.S. Boyer Ozurdex PLACID Study Group Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema Ophthalmology 120 2013 1843 1851
31. J.A. Haller, F. Bandello, R. Belfort Jr. Ozurdex GENEVA Study Group Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results Ophthalmology 118 2011 2453 2460
32. D.M. Brown, Q.D. Nguyen, D.M. Marcus RIDE and RISE Research Group Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE Ophthalmology 120 2013 2013 2022